OBJECTIVE - To determine whether an LHRH agonist, ATRIGEL(®) polymer-delivered, subcutaneous, leuprolide acetate (ADSC-LA) formulations suppressed testosterone to levels ≤20 ng/dL.
SUBJECT/PATIENTS AND METHODS - Data from four open-label, fixed-dose studies were evaluated.